Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core ...
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a small biotechnology company focused on regenerative medicine and cell-based therapeutic development. The company’s reported strategy centers on adult stem cell treatment concepts and immunology-linked regenerative approaches, aiming to translate biological therapeutics into potential treatments across several medical specialties. From a business ...Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a small biotechnology company focused on regenerative medicine and cell-based therapeutic development. The company’s reported strategy centers on adult stem cell treatment concepts and immunology-linked regenerative approaches, aiming to translate biological therapeutics into potential treatments across several medical specialties. From a business perspective, CELZ operates as a development-stage biotech with a narrow operating footprint (reported full-time employees: 4), which is typical for companies investing heavily in R&D, platform building, and clinical planning rather than mass commercialization.
On the product side, CELZ’s described therapeutic offerings and program concepts span multiple indications. Examples referenced include CaverStem (targeted toward erectile dysfunction), FemCelz (aimed at restoring genital sensitivity and alleviating dryness), StemSpine (developed for chronic lower back pain), ImmCelz (intended for stroke patients), and OvaStem (for female infertility). The company is also described as working within regenerative approaches across immunotherapy, endocrinology, urology, gynecology, and orthopedics, suggesting a platform-like orientation where biological and immunologic mechanisms are leveraged across different clinical areas.
From a services/operations angle, the company’s activities commonly involve R&D planning, preclinical-to-clinical translation, and ongoing work to advance a pipeline of cell-based therapies. However, the provided financial snapshot shows metrics consistent with a company that has not yet achieved sustainable profitability: profitability ratios such as return on assets and return on equity are strongly negative, and margins (gross/operating/net) are also reported as deeply negative in the provided trailing-twelve-month view. Market data in the provided snapshot indicates a small market capitalization (around $2.84M) and a relatively wide trading range (roughly $0.62–$6.25), consistent with higher volatility often observed in early-stage biotech equities.
In terms of cost structure and balance-sheet dynamics, the snapshot includes very high values for some current-ratio-related measures and working capital figures, alongside negative operating and free cash flow measures (free cash flow to equity and firm reported as negative in the snapshot). These patterns can imply that ongoing cash burn and investment in research and development are not yet matched by revenue generation sufficient for positive cash flow. As a result, funding and cash management are likely key operational priorities.
Key people include Timothy Warbington (CEO and co-founder) and other leadership such as Donald Dickerson (CFO). Looking ahead, the company’s “wishes” or strategic direction implied by the available information is to push its regenerative immunotherapy/cell-based programs forward—advancing pipeline candidates toward clinical validation and, ultimately, broader therapeutic impact. For investors and stakeholders, the principal focus is typically progress in development milestones, regulatory/clinical execution, and evidence that the company’s stem-cell-linked product concepts can translate into clinically meaningful outcomes.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$6000
-45.5%
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-6.0M
-9.1%
-7.6%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+63.4%
+5.7%
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-102380.2%
-96.1%
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-99916.8%
-100.1%
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-5.9M
-10.5%
-11.3%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-97607.4%
-102.5%
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.2%
—
-100.0%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
25.97x
+38.7%
-34.4%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
